Fingerprint
Dive into the research topics of 'Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically